# Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

> **NCT01439971** · PHASE1 · COMPLETED · sponsor: **Catalyst Biosciences** · enrollment: 29 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** PF-05280602
- **BIOLOGICAL:** PF-05280602
- **BIOLOGICAL:** PF-05280602
- **BIOLOGICAL:** PF-05280602
- **BIOLOGICAL:** PF-05280602

## Key facts

- **NCT ID:** NCT01439971
- **Lead sponsor:** Catalyst Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01439971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01439971, "Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01439971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*